FCS Leaders Applaud Launch of NCODA Clinical Advances Summit to Address the Future of Cancer Care

Longstanding NCODA Leadership Reflects Commitment to Innovation, 
Education and Patient-Centered Care

FORT MYERS, Fla., Oct. 30, 2026 /PRNewswire/ -- As the NCODA 2026 International Fall Summit draws to a close, Florida Cancer Specialists & Research Institute, LLC (FCS) physicians and executive leaders praised NCODA's announcement of the inaugural Clinical Advances Summit (NCAS), scheduled for October 2027. The expanded conference will bring together a broader group of multidisciplinary and international oncology experts to explore the clinical innovations, research and emerging trends transforming cancer care.

FCS President & Managing Physician Lucio N. Gordan, MD, a member of NCODA's board of directors and executive council, has been named as co-chair of NCAS and will help shape the meeting's scientific direction. "As cancer care continues to evolve, collaboration among healthcare professionals is more important than ever," Dr. Gordan said. "Scientific progress reaches its full potential only when clinicians are prepared for what's ahead and equipped to translate emerging evidence into patient care."

The announcement was particularly meaningful for FCS, which has maintained a strong leadership presence within NCODA for many years and was well represented at this year's International Fall Summit, where the following were introduced among NCODA's inaugural Class of 2026 Fellows in recognition of their longstanding leadership, service and contributions that have helped shape the organization:

• Lucio N. Gordan, MD
• Paul Chadwick, FCS chief procurement officer and NCODA Executive Council member
• Austin Cox, PharmD, FCS vice president of pharmacy services and NCODA Executive Council member
• Chris Elder, PharmD, BCOP, 2026 International Fall Summit Planning Committee and 2024 recipient of NCODA's Living the Mission Award
• Ray Bailey, BPharm, RPH, retired FCS vice president of pharmacy services

FCS CEO Ryan Ciarrocchi said, "This recognition reflects the collective efforts and impact of these dedicated professionals working to advance the future of cancer care. FCS is proud to be part of NCODA's mission and thoughtful plan forward to foster professional growth and help oncology teams translate innovation into meaningful improvements in care and outcomes."

Dr. Gordan welcomed participants to this year's flagship annual conference on behalf of FCS as the Host Practice. FCS panelists included:

• Paul Chadwick: "Implementing 505(b)(2) Products at Scale in Community Oncology Network"
• Constance Rim, PharmD, BCOP: "PQI in Action: Elevating Practice Through Team-Based Care"

"This next chapter will be especially exciting," said Dr. Gordan. "Building on a strong foundation, we will expand collaboration and elevate emerging research to advance better outcomes for patients everywhere."

About Florida Cancer Specialists & Research Institute, LLC: (FLCancer.com)
For more than 40 years, Florida Cancer Specialists & Research Institute (FCS) has embraced innovation to deliver world-class care and drive the dramatic transformation of oncology care through its robust clinical research program.

FCS provides patients with access to a wide range of clinical trials, positioning it as a leader in research among private oncology practices in Florida and across the country. Through its robust clinical research program with Sarah Cannon Research Institute (SCRI) and a suite of independent site management programs, with advanced clinical trial matching technology, FCS offers patients innovative therapies close to home. Each year, FCS conducts more than 180 active clinical trials that directly elevate patient care and accelerate progress in oncology. Many of the cancer drugs approved by the FDA in the U.S over the past decade were accessible to patients at FCS through clinical trial participation before receiving approval.

Our outstanding team of highly trained and dedicated physicians is committed to delivering tailored treatment plans that make the best use of cutting-edge precision oncology advancements to enhance patient outcomes.

SOURCE Florida Cancer Specialists & Research Institute